Related Articles
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer
Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer
Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases
Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first‑line treatment of metastatic colorectal cancer